Evaluation of the Magneto eTrieve™ PE Kit for Endovascular Thrombectomy in Subjects With Acute Pulmonary Embolism

Inclusion Criteria: * Age ≥ 18 years * Clinical signs, symptoms, and presentation consistent with acute pulmonary embolism (PE) * PE symptom duration ≤ 14 days * Filling defect in at least one main or lobar pulmonary artery on CTA * Right ventricle / left ventricle (RV/LV) ratio ≥ 0.9 on CTA (Investigator's reading) * Systolic blood pressure ≥ 90 mmHg * Stable heart rate \< 130 BPM prior to the index procedure * Anatomy that, in the opinion of the interventionalist, allows safe passage of the eTrieve™ catheters * Written informed consent Exclusion Criteria: * Patients with a combined reason for their decompensation (e.g., a patient with both sepsis and PE) * PE within 3 months prior to screening assessment * Thrombolytic use within 30 days prior to baseline CTA * Pulmonary hypertension with peak systolic PAP \> 70 mmHg * Inotrope or vasopressor requirement after fluid administration to keep the systolic blood pressure ≥ 90 mmHg * Fraction of inspired Oxygen (FiO2) requirement \> 40% or supplemental oxygen \> 6 LPM to keep oxygen saturation \> 90% * Any of the following laboratory findings (within 6 hours prior to index procedure): 1. Hematocrit \< 28% 2. Platelets \< 100,000/µL 3. Serum creatinine \> 1.8 mg/dL 4. INR \> 3 * Major trauma Injury Severity Score (ISS) \> 15 within 14 days prior to screening assessment * Intracardiac lead in right ventricle, right atrium or coronary sinus, placed within 6 months prior to screening assessment * Known presence of intracardiac clot * Cardiovascular or pulmonary surgery within last 7 days * Active malignancy and / or on chemotherapy * Known bleeding diathesis or coagulation disorder * Left bundle branch block * History of severe or chronic pulmonary arterial hypertension * History of left ventricular ejection fraction ≤ 30% * History of decompensated heart failure * History of underlying oxygen dependent lung disease * History of chest irradiation * History of Heparin Induced Thrombocytopenia (HIT) * Any contraindication to systemic therapeutic doses of heparin or other anticoagulants * Known anaphylactic reaction to radiographic contrast agents that cannot be adequately pre-medicated * Known hypersensitivity or contraindication to procedural medications which cannot be adequately managed medically * Imaging evidence or other evidence that suggests, in the opinion of the investigator, the subject is not appropriate for mechanical thrombectomy intervention * Life expectancy of \< 90 days as determined by the investigator * Co-morbid condition(s) that, in the opinion of the investigator, could limit the patient's ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study * Female who is pregnant or nursing * Current participation in another investigational drug or device treatment study * Previous enrollment in the eTrieve™ II Study